Pyxis Oncology Inc [PYXS] stock prices are up 7.29% to $5.15 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PYXS shares have gain 10.75% over the last week, with a monthly amount glided 48.84%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 04, 2025, and set its price target to $5. On November 21, 2024, downgrade downgraded it’s rating to Mkt Perform. Stephens started tracking the stock assigning an Overweight rating and suggested a price target of $13 on November 08, 2024. Stifel initiated its recommendation with a Buy and recommended $10 as its price target on August 08, 2024. In a note dated February 09, 2024, BTIG Research initiated a Buy rating and provided a target price of $8 on this stock.
The stock price of Pyxis Oncology Inc [PYXS] has been fluctuating between $0.83 and $5.11 over the past year. Currently, Wall Street analysts expect the stock to reach $7.5 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $5.15 at the most recent close of the market. An investor can expect a potential return of 45.63% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -17.07%, Pretax Profit Margin comes in at -15.91%, and Net Profit Margin reading is -15.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.92, Equity is -1.02 and Total Capital is -1.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.97 points at the first support level, and at 4.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.29, and for the 2nd resistance point, it is at 5.42.
Ratios To Look Out For
It’s worth pointing out that Pyxis Oncology Inc [NASDAQ:PYXS]’s Current Ratio is 4.29. In addition, the Quick Ratio stands at 4.29 and the Cash Ratio stands at 0.46. Considering the valuation of this stock, the price to sales ratio is 113.71, the price to book ratio is 4.65.
Transactions by insiders
Recent insider trading involved HUMPHREY RACHEL, Director, that happened on Apr 21 ’25 when 13896.0 shares were purchased. Director, HUMPHREY RACHEL completed a deal on Apr 17 ’25 to buy 200.0 shares. Meanwhile, Director HUMPHREY RACHEL bought 1400.0 shares on Apr 14 ’25.
